The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2016 | Increasing overall survival in oligometastatic lung cancer patients
Matthias Guckenberger, MD of University Hospital Zurich, Switzerland talks about the shifting boundary between cure and palliation. Traditionally patients with metastatic disease have been considered palliative, where there is a lower value of aggressive local radical treatment. Recently, more of these patients are classified as oligometastatic. These patients have a limited number of metastases in a limited number of origins. In these patients, it is increasingly possible to offer a curative approach with stereotactic body radiotherapy (SBRT), surgery and other techniques, and we see long-term overall survival (OS). However, patient selection must be done better to select patients which might benefit from adding local treatment to systemic treatment, and which might not benefit. Recorded at the 2016 World Conference of Lung Cancer (WCLC) of the International Association for the Study of Lung Cancer (IASLC) in Vienna, Austria.
